AMO Pharma Limited (AMO Pharma) announced initiation of a phase 2 clinical study in the U.K. for AMO-02 (tideglusib) on August 10, 2016. This phase 2 exploratory study focuses on adult and adolescent patients with congenital and juvenile onset myotonic dystrophy. This is the first sponsor-led clinical study evaluating an investigational therapy in this patient group as part of a development program.
For AMO Pharma's announcement on the clinical trial, click here. Click here for more detail on the trial at clinicaltrials.gov. For more information on AMO Pharma, click here.
